Ovarian metastases in stage IB carcinoma of the cervix: A Gynecologic Oncology Group study8,9

https://doi.org/10.1016/0002-9378(92)91828-XGet rights and content

Surgical and pathologic findings at laparotomy for radical hysterectomy in 990 patients with clinical stage IB carcinoma of the cervix were analyzed to determine the frequency of metastases to the ovary. Ovarian spread was identified in 4 of 770 (0.5%) patients with squamous carcinoma and 2 of 121 (1.7%) with adenocarcinoma. No patients with adenosquamous carcinoma (n = 82) or other histologic types (n = 17) had ovarian metastases. Although the frequency of metastases was greater among patients with adenocarcinoma, this was not statistically significant (p = 0.19, Fisher's exact test). All 6 patients with ovarian metastases had other evidence of extracervical disease. Three underwent radical hysterectomy and bilateral salpingo-oophorectomy. Of these, one patient received extended field radiotherapy and died of disease 18 months after diagnosis. Two patients, one treated with combination chemotherapy and one with no adjunctive therapy, are alive without evidence of disease at 59 and 62 months, respectively. Three patients underwent exploratory laparotomy with salpingo-oophorectomy and lymphadenectomy without hysterectomy. All three patients died of disease at 2, 3, and 30 months; the first and last patient received adjunctive radiotherapy. Not all patients underwent oophorectomy. Of 347 patients with at least unilateral ovarian preservation, no postoperative pelvic radiotherapy, and no gross extracervical disease or metastasis to the paraaortic nodes, pelvic recurrence developed in 16. There was no excess of pelvic recurrences in patients with adenocarcinoma (0/41) or adenosquamous carcinoma (1 /29, 3.4%) when compared with those with squamous carcinoma (15/270, 5.6%). This suggests no excess of occult ovarian metastases in nonsquamous tumors of the cervix. There is no evidence in these data of an increased risk of ovarian preservation in patients with stage IB carcinoma of the cervix with no gross extracervical disease.

References (11)

There are more references available in the full text version of this article.

Cited by (0)

8

For a complete list of participating institutions and grant support, see end of article.

9

Presented at the Thirty-eighth Annual Meeting of the American College of Obstetricians and Gynecologists, San Francisco, California, May 7–10, 1990.

a

From the Section of Gynecologic Oncology, Indiana University Medical School

b

Rosxvell Park Memorial Institute

c

Division of Gynecologic Oncology, Georgetown University

d

Division of Gynecologic Oncology, the Department of Obstetrics and Gynecology, University of Miami

e

Department of Obstetrics and Gynecology, Medical University of South Carolina

f

Department of Obstetrics and Gynecology, University of Colorado School of Medicine, and the Gynecology Tumor Service, St. Luke's Hospital

g

Department of Pathology, The Milton S. Hershey Medical Center of Pennsylvania State University.

View full text